Bioxodes

TLDR

Bioxodes is a clinical-stage biopharmaceutical company developing Ir-CPI (BIOX-101), a first-in-class drug candidate for hemorrhagic stroke patients.

Overview

Bioxodes develops an innovative pipeline in thrombo-inflammation with BIOX-101 as its lead candidate. The drug has a unique mechanism of action targeting neutrophils and coagulation factors (FXIIa, FXIa) for the prevention of thrombosis and neuroinflammation in hemorrhagic stroke patients.